Elevance Health (ELV – Research Report) received a Buy rating and a $485.00 price target from Cantor Fitzgerald analyst Sarah James yesterday.

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Elevance Health (ELV – Research Report), with a ...

It is time for patients to regain their voice in this debate and for physicians to use their knowledge and voices to advocate for them. We must protect Hoosier patients. Need a break? Play the USA ...

Elevance Health delivered earnings and 2025 guidance that broadly met analysts’ expectations, likely providing some relief to investors after a challenging quarter. The fourth-quarter results marked t ...

Health-care companies rose sharply amid strong earnings.

Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting." ...

Elevance Health's quarterly dividend has been increased by 5% to $1.71 per share. The company's president and CEO, Gail K. Boudreaux, expressed the commitment to simplifying the healthcare experience ...

Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting." ...

Elevance Health, Inc. ELV reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.84, which surpassed the Zacks Consensus Estimate by 1.1%. However, the bottom line deteriorated 31.7% ...